- Home
- DAWN vs CBRE Comparison
DAWN vs CBRE Comparison
Compare DAWN & CBRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- CBRE
- Stock Information
- Founded
- DAWN 2018
- CBRE 1906
- Country
- DAWN United States
- CBRE United States
- Employees
- DAWN N/A
- CBRE N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- CBRE Real Estate
- Sector
- DAWN Health Care
- CBRE Finance
- Exchange
- DAWN Nasdaq
- CBRE Nasdaq
- Market Cap
- DAWN 1.3B
- CBRE 40.1B
- IPO Year
- DAWN 2021
- CBRE 2004
- Fundamental
- Price
- DAWN $12.79
- CBRE $129.30
- Analyst Decision
- DAWN Strong Buy
- CBRE Buy
- Analyst Count
- DAWN 7
- CBRE 9
- Target Price
- DAWN $36.17
- CBRE $133.33
- AVG Volume (30 Days)
- DAWN 1.0M
- CBRE 2.3M
- Earning Date
- DAWN 10-30-2024
- CBRE 02-13-2025
- Dividend Yield
- DAWN N/A
- CBRE N/A
- EPS Growth
- DAWN N/A
- CBRE 66.15
- EPS
- DAWN N/A
- CBRE 3.10
- Revenue
- DAWN $101,953,000.00
- CBRE $34,313,000,000.00
- Revenue This Year
- DAWN N/A
- CBRE $13.52
- Revenue Next Year
- DAWN $36.10
- CBRE $11.01
- P/E Ratio
- DAWN N/A
- CBRE $41.62
- Revenue Growth
- DAWN N/A
- CBRE 10.00
- 52 Week Low
- DAWN $11.94
- CBRE $82.75
- 52 Week High
- DAWN $18.07
- CBRE $142.00
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- CBRE 41.60
- Support Level
- DAWN $12.26
- CBRE $125.38
- Resistance Level
- DAWN $12.81
- CBRE $140.70
- Average True Range (ATR)
- DAWN 0.52
- CBRE 3.43
- MACD
- DAWN -0.05
- CBRE -1.51
- Stochastic Oscillator
- DAWN 28.94
- CBRE 25.59
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.